From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Infections
Number of patients (N = 50)
HIV
16
HBV
10
HCV
15
HIV/HBV co-infection
1
HIV/HCV co-infection
3
HBV/HCV co-infection
4
HIV/HBV/HCV co-infection